A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 11 Dec 2018 Primary endpoint has been met. (Change from baseline in mean sitting systolic blood pressure (msSBP) between LCZ696 200 mg versus olmesartan 20 mg)
- 11 Dec 2018 Results published in the Journal of Clinical Hypertension (Greenwich)
- 11 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.